Instil Bio, Inc. (5GT0)
XFRA 
NASDAQ (CM) Primary XFRA Summary
5GT0 Chart
Instil Bio shares slide on discontinuation of lead clinical programs
Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to discontinue development of its lead clinical assets AXN-2510 and AXN-27M and to terminate its partnership with ImmuneOnco. Analysts at Baird downgraded the stock to ‘Neutral' on the update.
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Instil Bio, Inc. (5GT0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Instil Bio, Inc. ever had a stock split?
Instil Bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bronson Crouch CEO | XFRA Exchange | US45783C2008 ISIN |
| US Country | 14 Employees | - Last Dividend | 8 Dec 2023 Last Split | 19 Mar 2021 IPO Date |
Overview
Instil Bio, Inc. is a forward-thinking clinical-stage biopharmaceutical company established in 2018, with its headquarters positioned in Dallas, Texas. At its core, Instil Bio is devoted to pioneering a comprehensive pipeline of innovative therapies aimed at transforming cancer treatment. The company's focus lies significantly in the development of cell therapies using tumor infiltrating lymphocytes (TIL), a revolutionary approach that holds promise in offering new hope to cancer patients. Leveraging cutting-edge science and a dedicated team of experts, Instil Bio is pushing the boundaries of cancer therapy, committed to making a significant impact on the lives of patients by unlocking the power of the body's immune system to fight cancer more effectively.
Products and Services
- Cell Therapy of Tumor Infiltrating Lymphocyte (TIL) for Cancer Treatment
Instil Bio is at the forefront of developing cell therapies that utilize Tumor Infiltrating Lymphocytes (TILs) for the treatment of cancer. This innovative treatment harnesses the patient's immune system, particularly using lymphocytes that have infiltrated the tumor, to recognize and kill cancer cells. By extracting these cells, expanding their numbers significantly in the laboratory, and then reintroducing them into the patient's body, this therapy offers a potent and personalized approach to battling cancer.
- CoStAR-TIL Technology
Alongside its primary TIL therapies, Instil Bio is also pioneering the early-stage development of CoStAR-TIL, a novel technology designed to enhance the effectiveness of TIL therapies. This technology represents a next-generation approach in the fight against cancer, aiming to improve the specificity and stamina of TIL cells, thereby increasing the overall success rate of the therapy. CoStAR-TIL and other innovative TIL technologies are crucial components of Instil Bio’s strategy to lead in the cell therapy landscape for cancer treatment.
